ICIs (CTLA-4, PD-1, or PD-L1) (27) are widely used to treat solid tumors (28), with the aim of utilizing host immunity to combat cancer, making them promising strategies for treating solid tumors. The gene discussed is PDCD1; the disease is cancer.